natgillin/translations-raw huggingface dataset:
The CVMP working parties and the Joint CPMP/ CVMP Quality Working Party (see Chapter 4) met regularly in 2000.
Budgeten har övervakats och justerats, särskilt som svar på ökade intäkter och finansiering av nya uppgifter, exempelvis särläkemedel och PERF II.
Details of notes for guidance prepared by the working parties for the CVMP are given in Annex 11.
Omstrukturering och renovering av EMEA: s kontor som en del i byggnadspolicyn.
Meetings in 2000
Personal, budget och lokaler Under år 2000 upprättades en personaldatabas som kommer att underlätta personaladministrationen, särskilt uppgifter om ledighet, utvärderingsrapporter och andra personaluppgifter.
consider documents approved in 2000
EMEA: s personal per nationalitet
Gabriella CONTI, then Cornelia IBRAHIM*
Belgien 7% Storbritannien Danmark 22% 5% Tyskland 12%
Paul-Pierre PASTORET
Sverige
4
Grekland 4%
4
Finland 4% Spanien Portugal 7%
Chapter 4 Technical coordination activities
4%
activities 19%
Österrike 1%
Administrative Special activities to be earmarked 8%
Nederländerna Frankrike 4% 12% Italien Irland Luxemburg 8% 5% 0%
49 EMEA General Report 2000
EMEA/ MB/ 050/ 00 Allmän rapport 2000
Coordination of inspections for centralised procedures
EMEA: s personal per kategori och kön
Inspections carried-out for centralised procedures 1998-2000
Sida 51/ 84
1998
Män
1999
Kvinnor
2000
Personalen vid enheten för utvärdering av humanläkemedel, totalt ett hundratal personer, kunde flytta till de nya kontorsutrymmena i mars 2000.
The number of good manufacturing practice (GMP) inspections performed in 2000 was higher than expected due to a carry-over of 16 inspection requests from 1999 and a significant increase in requests in 2000.
De lokalansvariga började också planera och genomföra ett annat stort utrustningsprojekt under år 2000, nämligen ytterligare sammanträdesrum och lokaler för delegaterna på tredje våningen.
A database of GMP inspections was completed in 2000 in order to provide management reports and information for coordinating inspections and to provide a direct input of data into the SIAMED application tracking system.
EMEA/ MB/ 050/ 00 Allmän rapport 2000 Renoveringsplaner för plan
This included a significant number of inspections performed outside of the EU.
Förklaring Rum 3A – konferensrum
Sampling and testing
(115 personer)
The activities of the network are coordinated by the European Department for the Quality of Medicines (Council of Europe) and the EMEA.
Rum 3B – mötesrum med flera funktioner (40 personer)
The 1999-2000 testing programme was implemented for 35 centrally authorised products.
Rum 3C – mötesrum och videokonferens - svit (35 personer) 3B
No major problems were identified during the testing programme.
EMEA/ MB/ 050/ 00 Allmän rapport 2000 Redovisning
A testing programme for 2001 was agreed in 2000.
Ett valutaterminssystem förhandlades fram med EMEA: s banker för att en svag euro skall få så små effekter som möjligt på EMEA: s ekonomi.
A total of 5 reports on quality problems concerning centrally authorised products were received and monitored by the EMEA, leading to 2 product recalls.
År 2000 gjordes 6 761 betalningar och 1 084 intäktsposter behandlades, vilket innebär en ökning med 11% resp 45% jämfört med 1999.
50 EMEA General Report 2000
2000
Mutual recognition agreements
Inkomstbringande verksamheters volym 1999 och 2000
On-going discussions or MRAs in transition period
Inkomster från avgifter och administrativa kostnader
EC – Canada MRA
Övriga inkomster
The equivalence assessment between EC and Canada of GMP compliance systems was completed in 2000.
EMEA/ MB/ 050/ 00 Allmän rapport 2000 Bilagor
EC – US MRA
Sida 54/ 84
The evaluation of the EC and US legislation and GMP guidelines and compliance systems continued in 2000.
EMEA: s kontaktpersoner och referensdokument
The EU finalised its plans for the first evaluation visits to the US in March 2001.
EMEA: s budgetar 1999 till 2001
Current projections by the US indicate that the assessments of the EU would not be finished by the November 2001 end of the transition period.
Styrelsemedlemmar
EC – Switzerland MRA
CPMP- medlemmar
The text of the agreement and explanatory notes were agreed and ratified in May 2000.
CVMP- medlemmar
The date of entry into force is expected to be summer 2001.
Behöriga nationella myndigheter
EC – Australia MRA and EC – New Zealand MRA (veterinary medicinal products)
CPMP: s yttranden 2000 om humanläkemedel
Activities continued in 2000 to evaluate equivalence of these agreements.
CVMP: s yttranden 2000 om veterinärmedicinska läkemedel
MRAs in force
10.
EC – Australia MRA and EC – New Zealand MRA (human medicinal products)
11.
Activities in 2000 included the development of a maintenance programme and other documents to facilitate the operation.
EMEA: s riktlinjedokument 2000
Alert systems and certification schemes have been agreed in principle.
EMEA/ MB/ 050/ 00 Allmän rapport 2000 Bilaga 1 EMEA: s kontaktpersoner och referensdokument
Certification of medicinal products
Kontaktpersoner inom EMEA
New arrangements for requesting certificates of a medicinal product were introduced in 2000 and posted on the EMEA web site.
Biverkningsbevakning och rapportering om defekta läkemedel
The efficiency of certificate production was improved by generating certificates directly from a database, resulting in an improved service in terms of time to issue of an average 4.9 days for 2000.
Den löpande övervakningen av läkemedels säkerhet efter det att de godkänts för försäljning (” biverk - ningsbevakning ”) är en viktig del av det arbete som utförs av de behöriga nationella myndigheterna och EMEA.
An internal audit of procedures was conducted in 2000, leading to improved internal communication of pharmacovigilance rapid alerts and arrangements for defective product reporting.
EMEA får in säkerhetsrapporter från EU- länderna och andra länder om centralt godkända läkemedel och samordnar verksamheten med anknytning till läkemedels säkerhet och kvalitet.
The number of certificates requested fell from 9 652 in 1999 to 8 357 in 2000.
Frågor rörande biverkningsbevakning avseende humanläkemedel
Joint CPMP/ CVMP Quality working party
Kontaktperson Noël WATHION Tfn direkt (44- 20) 74 18 85 92 E- post: noel. wathion@ emea. eudra. org
The group also liaised with the safety and efficacy working parties in the development of guidelines of common interest.
Frågor rörande biverkningsbevakning avseende veterinärmedicinska läkemedel
A meeting with interested parties took place in October 2000.
Kontaktperson Barbara FREISCHEM Tfn direkt (44- 20) 74 18 85 81 E- post: barbara. freischem@ emea. eudra. org
51 EMEA General Report 2000
Defekta läkemedel och andra kvalitetsfrågor
4.2 Document management and publishing
Kontaktperson Stephen FAIRCHILD Faxnummer för snabblarm om defekta läkemedel Tfn direkt (44- 20) 74 18 85 90 E- post: stephen. fairchild@ emea. eudra. org
Product information
Läkemedelscertifikat
A joint project on product information management between EMEA and the European Federation of Pharmaceutical Industries and Associations was launched in 2000.
Ett sådant certifikat innehåller uppgifter om att ett läkemedel är godkänt för försäljning i EU och om läkemedlets status i fråga om god tillverkningssed (GMP).
About 150 delegates from national competent authorities, pharmaceutical industry and software companies attended a workshop in September 2000 and welcomed the initiative.
Certifikaten är avsedda som stöddokumentation vid ansökan om godkännande för försäljning i länder utanför EU och vid export till sådana länder.
An average of 400 to 500 documents usually have to be revised for each product per change in product information.
Frågor rörande certifikat för centralt godkända humanläkemedel och veterinärmedicinska läkemedel
The product information templates on the EMEA web site were reviewed in 2000 and the template for summary of product characteristics, labelling and package leaflet (template 1a) was revised in all 11 official EU languages following the adoption of the December 1999 Guideline on summary of product characteristics and is available on the EMEA web site.
Kontaktperson Jonna SUNELL- HUET Tfn direkt (44- 20) 74 18 84 65 E- post: certificate@ emea. eudra. org
Electronic submission
Dokumentservice
Electronic submission will facilitate data exchange between applicants and marketing authorisation holders with the EMEA.
EMEA har publicerat ett stort antal dokument, bl. a. pressmeddelanden, allmän information, årsrapporter och arbetsprogram.
There are activities on product information management, marketing authorisation applications, maximum residue limits and the Xdossier Internet draft.
Dessa och andra dokument är tillgängliga på webbplatsen http: www. emea. eu. int eller kan rekvireras skriftligen från:
The EMEA actively contributed in 2000 to discussions concerning the electronic common technical dossier (eCTD) and demonstrated a template for the eCTD at the ICH5 meeting in San Diego.
Subscription Service European Agency for the Evaluation of Medicinal Products 7 Westferry Circus Canary Wharf London E14 4HB Storbritannien
An electronic submission development web site was established in 2000 to provide information on work in progress: http: / /esubmission. eudra. org
Det finns en prenumerationstjänst omfattande alla offentliga EMEA- dokument, med distribution av dokumenten elektroniskt eller i pappersform.
Document management
Mer information kan erhållas från adressen ovan eller från
A public tender procedure was conducted in 2000 for the selection of an electronic document management system.
Kontaktperson Iro MAVROPOULOS Tfn direkt (44- 20) 74 18 85 82 E- post: subscriptions@ emea. eudra. org
A feasibility study was begun at the end of 2000 prior to the final selection of the system provider.
Kontaktperson Amanda BOSWORTH Tfn direkt (44- 20) 74 18 84 08 E- post: amanda. bosworth@ emea. eudra. org
The system will focus in the initial stages on document control for the scientific advice and modular EPAR processes.
Begäran om att få granska förteckningar över europeiska experter
The sector coordinated the compilation of the EMEA catalogue of documents, which was published for the first time in November 2000.
Förteckningen över europeiska experter är tillgänglig för granskning på begäran vid EMEA: s kontor.
The number of subscribers for EMEA documents fell in 2000, with users increasingly using the web site to access information directly.
Förteckningen över experter på veterinärmedicinska
52 EMEA General Report 2000
vet_ experts@ emea. eudra. org
4.3 Conference services
inspectors_ experts@ emea. eudra. org
EMEA meetings
Massmediekontakter
Activities relating to the organisation of meetings at the EMEA increased by over 37% in 2000.
Antoine CUVILLIER Tfn direkt (44- 20) 74 18 84 28 E- post: antoine. cuvillier@ emea. eudra. org
Meetings at the EMEA 1995-2000
EMEA/ MB/ 050/ 00 Allmän rapport 2000 EU: s officiella publikationer
350
Sida 57/ 84
300
Publikationer i serien, liksom exemplar av Europeiska gemenskapernas officiella tidning (EGT), kan beställas från:
250
Byrån för Europeiska gemenskapernas officiella publikationer 2, rue de Mercier L - 2985 Luxemburg
200
eller hämtas på webbplatsen EudraLex: http: // pharmacos. eudra. org/ eudralex/ index. htm
150
EMEA- dokument
100
Första allmänna rapporten om verksamheten vid Europeiska läkemedelsmyndigheten, 1995 (ISBN 92- 827- 7491- 0, Byrån för Europeiska gemenskapernas officiella publikationer) Andra allmänna rapporten om verksamheten vid Europeiska läkemedelsmyndigheten, 1996 (ISBN 92- 9155- 002- 7, Byrån för Europeiska gemenskapernas officiella publikationer) Tredje allmänna rapporten om verksamheten vid Europeiska läkemedelsmyndigheten, 1997 (ISBN 92- 9155- 010- 8, Byrån för Europeiska gemenskapernas officiella publikationer) Fjärde allmänna rapporten om verksamheten vid Europeiska läkemedelsmyndigheten, 1998 (ISBN 92- 9155- 018- 3, Byrån för Europeiska gemenskapernas officiella publikationer) Femte allmänna rapporten om verksamheten vid Europeiska läkemedelsmyndigheten, 1999 (ISBN 92- 9155- 026- 4, EMEA) Uttalande om principerna för samverkan mellan de nationella behöriga myndigheterna och Europeiska myndigheten för utvärdering av läkemedel (EMEA/ MB/ 013/ 97 Budgetförordning för EMEA (EMEA/ MB/ 011/ 97) Verkställande direktörens beslut av den 3 december 1997 om bestämmelser om tillgång till EMEA: s handlingar (EDIR/ 016/ 1997)) Verkställande direktörens beslut av den 1 juni 1999 om samarbetet med Europeiska byrån för bedrägeribekämpning (OLAF) (EDIR/ 006/ 1999) Katalog över offentliga EMEA- dokument (uppdateras regelbundet) Uppförandekodex för EMEA (EMEA/ D/ 37674/ 99)
50
Sector for Document management and publishing European Agency for the Evaluation of Medicinal Products 7 Westferry Circus Canary Wharf London E14 4HB Storbritannien
0
EMEA/ MB/ 050/ 00 Allmän rapport 2000 Bilaga 2 EMEA: s budgetar 1999 till 2001
1995
Sida 58/ 84
1996
1999( 1)
1997
2000( 2)
1998
2001( 3)
1999
(31. 12. 1999)
2000
(per den 31. 12. 2000)
A survey in 2000 to measure the level of satisfaction of the delegates showed a high level of satisfaction with the level of service provided by the EMEA.
(per den 20. 12. 2000)
Progress was made in planning the new conference rooms on floor 3.
Löner Extern personal och andra stödpersoner
Pan-European Regulatory Forum
074 905 955 456
The contract for the conduct of the first phase of the Pan-European Regulatory Forum on Pharmaceuticals (PERF I) was completed in 2000.
18 1
53 EMEA General Report 2000
493 000 058 000
54 EMEA General Report 2000
33, 45% 1, 91%
Chapter 5 Administration
772 000 379 000
Overview of the Administration Unit
35, 15% 2, 23%
Overview of the Administration Unit
Övriga personalkostnader Summa avdelning 1 Byggnader och utrustning
Head of Unit Head of Sector for personnel, budget and facilities Head of Sector for accounting
1 17
Andreas POTT Frances NUTTALL Gerard O’ MALLEY
191 570 221 931
The Administration Unit is responsible for personnel, budget,
2, 89% 41, 82%
accounting and facilities.
350 000 901 000
In addition, a number of projects set out in the Work Programme have been completed:
2, 44% 37, 80%
• Euro consolidated into the financial and budgetary proceedings of the Agency • recruitment targets achieved • budget monitored and adjusted, particularly in response to increased revenues and the financing of new tasks such as orphan medicinal products and PERF II • preparation of organisational restructuring of the Unit for the Evaluation of Medicines for Human Use • restructuring and refurbishment of EMEA offices as part of building policy
1 24
Personnel, budget and facilities
501 000 652 000
A personnel database was selected in 2000 that will facilitate personnel administration, in particular leave records, evaluation reports and other personnel details.
Hyra och avgifter Databehandling Övriga kapitalkostnader Porto och kommunikationer
EMEA staff members by category and sex
136 038 034 357 824 960 370 754
70
5 2 2
60
5 1
50
1 6
s Male
194 926 561 071
s Female
2, 90% 15, 93%
40
1 12
30
593 000 061 720
20
2, 88% 21, 82%
10
1 10
0
3 13
Category A
274 441 894 457 -- 93 650 137 130
Category B
7, 95% 33, 74% 0, 00% 0, 23% 0, 33%
Category C
3 18
Category D
5 000 150 000
55 EMEA General Report 2000
6, 31% 33, 79% 0, 00% 0, 01% 0, 27%
EMEA staff members by nationality
565 000 658 000 428 000 180 000 220 000
Belgium 7%
42, 25%
UK 22%
22
Denmark 5%
324 500
Germany 12%
40, 38%
Sweden 5% Greece 4%
27
Finland 4%
051 000
Portugal 4% Austria 1% Netherlands 4%
43, 68%
Spain 7%
100, 00%
France 12%
100, 00%
Luxembourg 0%
100, 00%
Italy 8%
SUMMA KOSTNADER
Ireland 5%
41
By constant budget monitoring and cost control the budget team successfully coordinated the execution of the budget and strove to achieve cost efficiencies.
182 680
A detailed review of training needs and the provision of training was undertaken during the year to improve the opportunities available to staff members.
55
Additional office space of 1 460 m2 on the seventh floor of 7 Westferry Circus was occupied in 2000 to complement the existing three floors.
287 220
The work will be concluded in early 2001.
61 934 000
56 EMEA General Report 2000
Intäkter
Refurbishment plans for the third floor, EMEA offices
Avgifter Bidrag från EU Särskilt bidrag från EU för
3D 3C
28 10
3B 3A
952 500 481 649
Legend
70, 31% 25, 45%
Room 3A – conference room (115 people)
39 13
Room 3B – multi-function meeting room (40 people)
154 000 70, 82% 200 000 23, 88%
Room 3C – meeting room and video- conference suite (35 people)
42 610 000 14 700 000
Room 3D – meeting room (18 people)
68, 81% 23, 73%
Open area/ reception
särläkemedel Bidrag från EES Bidrag från EU- program (PERF)
Accounts
-- --
Further productivity gains were seen in 2000 as increases in the volume of transactions processed were absorbed without increasing staff numbers.
0, 00% 0, 00%
A forward exchange facility was negotiated with the Agency’ s banks to reduce to a minimum the effects of a weak Euro on the Agency’ s finances.
1
57 EMEA General Report 2000
000 000 1, 81% 245 220 0, 44%
Volume of payments made in 1999 and 2000
600 000 250 000
7000
0, 97% 0, 40%
6000
800 000
5000
1, 94%
s 1999
217 000 0, 39%
s 2000
2 440 000
4000
3, 94%
3000
Övriga inkomster
2000
948 531
1000
2, 30%
Building and facilities
471 000 2, 66%
Rapporters
1 334 000
Total
2, 15%
Volume of income operations in 1999 and 2000
SUMMA INKOMSTER Noter
1200
41 182 680
1000
100, 00%
s 1999
100, 00% 55 287 220
s 2000
61 934 000
800
100, 00%
600
(3) Budgeten för 2001: uppgifterna avser preliminära anslag.
400
EMEA/ MB/ 050/ 00 Allmän rapport 2000 Bilaga 3 Styrelsemedlemmar
200
Sida 59/ 84
Fee revenue and
Ordförande
Other revenue
André BROEKMANS (1)
Total
Medlemmar
administrative charges
Paul WEISSENBERG
58 EMEA General Report 2000
Belgique/ België Danmark
Annexes
André PAUWELS, Frans GOSSELINCKX Ib VALSBORG, Jytte LYNGVIG (5)
59 EMEA General Report 2000
Deutschland / Greece αδάλλΕ España France Ireland
Annexes
Hermann Josef PABEL, Gerhard Josef KOTHMANN, Vice ordförande Marios MARSELOS (6), Elias MOSSIALOS (7) María Victoria de la CUESTA GARCIA (8), Ramón PALOP BAIXAULI (9) Philippe DUNETON, Martin HIRSCH (10) Tom MOONEY, Colm GAYNOR (11)
EMEA contact points and reference documents
Italia Luxembourg Nederland
EMEA budgets 1998 to 2000
Nello MARTINI, Romano MARABELLI Mariette BACKES- LIES John LISMAN (12), Frits PLUIMERS
Members of the Management Board
Österreich Portugal Suomi/ Finland
Members of the Committee for Proprietary Medicinal Products
Alexander JENTZSCH, Ernst LUSZCZAK Miguel ANDRADE (13), Rógerio GASPAR (14) Pekka JÄRVINEN (15), Hannes WAHLROOS
Members of the Committee for Veterinary Medicinal Products
Sverige United Kingdom
Members of the Committee for Orphan Medicinal Products
Birgitta BRATTHALL, Anders BROSTRÖM Keith JONES, Michael RUTTER
National competent authority partners
Observatörer
CPMP opinions in 2000 on medicinal products for human use
Ísland Liechtenstein Norge/ Noreg
CVMP opinions in 2000 on medicinal products for veterinary use
Rannveig GUNNARSDÓTTIR, Ingolf PETERSEN Brigitte BATLINER, Peter MALIN Andreas DISEN, Gro Ramsten WESENBERG
10.
(2) Ersatte Dietrich HENSCHLER fr. o. m. mötet den 22 februari 2000.
COMP opinions in 2000 on orphan medicinal products
(3) Ersatte Jörn KECK fr. o. m. mötet den 22 februari 2000.
11.
(11) Ersatte John COSTELLOE fr. o. m. mötet den 22 februari 2000.
EMEA guidelines in 2000
(15) Ersatte Kimmo LEPPO fr. o. m. mötet den 22 februari 2000.
60 EMEA General Report 2000
EMEA/ MB/ 050/ 00 Allmän rapport 2000 Bilaga 4 Medlemmar i Kommittén för farmaceutiska specialiteter (CPMP) (1)
Annex 1:
Sida 60/ 84
EMEA contact points and reference documents
· Jean- Michel ALEXANDRE (France), ordförande
EMEA contact points
· · · ·
Pharmacovigilance and product defect reporting The constant monitoring of the safety of medicines after authorisation (‘ pharmacovigilance’) is an important part of the work of the national competent authorities and EMEA.
Fernando de ANDRÉS- TRELLÉS (España) Cristina AVENDAÑO (España) Michalis AVGERINOS (Ελλάδα/ Greece) Rolf BASS (Deutschland) (3)
For matters relating to pharmacovigilance for medicinal products for human use
· ·
Contact point Noël WATHION Direct telephone (44-20) 74 18 85 92 E-mail: noel. wathion@emea. eudra. org
Daniel BRASSEUR (Belgique/ België) Hans van BRONSWIJK (Nederland), vice ordförande (4)
For matters relating to pharmacovigilance for medicinal products for veterinary use
· · · · · · · · · ·
Contact point Barbara FREISCHEM Direct telephone (44-20) 74 18 85 81 E-mail: barbara. freischem@emea. eudra. org
Geert DE GREEF (Belgique/ België) Jens ERSBØLL (Danmark) Silvio GARATTINI (Italia) Jacqueline GENOUX- HAMES (Luxembourg) Willem van der GIESEN (Nederland) Lars GRAMSTAD (Norge/ Noreg) Manfred HAASE (Deutschland) Magnús JÓHANNSSON (Ísland) Tove KARLSUD (Norge/ Noreg) Pekka KURKI (Suomi/ Finland) (5)
For product defect and other quality-related matters
David LYONS (Ireland) Jose Guimarães MORAIS (Portugal) (6)
Contact point Stephen FAIRCHILD Fax number for defective product rapid alerts (44-20) 74 18 85 90 E-mail: stephen. fairchild@emea. eudra. org
Per NILSSON (Sverige) Jean- Louis ROBERT (Luxembourg) Frances ROTBLAT (United Kingdom) (7) Patrick SALMON (Ireland) (8)
Certificates of a medicinal product
· · · · · · · · · ·
The EMEA issues certificates of a medicinal product in conformity with the arrangements laid down by the World Health Organisation.
(2) Ersatte Gorm JENSEN fr. o. m. mötet i januari 2000.
These certify the marketing authorisation and good manufacturing status of medicinal products in the EU and are intended for use in support of marketing authorisation applications in and export to non-EU countries.
(8) Ersatte Mary TEELING fr. o. m. mötet i september 2000.
For enquiries concerning certificates for centrally Contact points authorised medicines for human or veterinary use Jonna SUNELL-HUET Direct telephone (44-20) 74 18 84 65 E-mail: certificate@emea. eudra. org
EMEA/ MB/ 050/ 00 Allmän rapport 2000 Bilaga 5 Medlemmar i Kommittén för veterinärmedicinska läkemedel (CVMP) (1)
These and other documents are available either on the Internet at http: / /www. emea. eu. int or by writing to:
· Reinhard KROKER (Deutschland), ordförande
Subscription Service European Agency for the Evaluation of Medicinal Products 7 Westferry Circus, Canary Wharf London E14 4HB UK
· · · · · · · · · · · · · · · ·
61 EMEA General Report 2000
Margarita ARBOIX (España) J.
A subscription service is available for all EMEA public documents, distributing documents electronically or in paper form.
Liisa KAARTINEN (Suomi/ Finland) Herman LENSING (Nederland) Jan LUTHMAN (Sverige) Agostino MACRI (Italia) Ioannis MALEMIS (Ελλάδα/ Greece) Maria Leonor MEISEL (Portugal) (3)
Further information can be obtained from the above address or from
· · · · · ·
Contact point Iro MAVROPOULOS Direct telephone (44-20) 74 18 85 82 E-mail: subscriptions@emea. eudra. org
Manfred MOOS (Deutschland) Gérard MOULIN (France) John O’ BRIEN (United Kingdom) Eugen OBERMAYR (Österreich) Sigurdur ÖRN HANSSON (Ísland) Orestis PAPADOPOULOS (Ελλάδα/ Greece) (4)
Requests for general information packs should be sent to
· · · · · ·
Contact point Amanda BOSWORTH Direct telephone (44-20) 74 18 84 08 E-mail: amanda. bosworth@emea. eudra. org
Paul- Pierre PASTORET (Belgique/ België) Margarida PRATAS (Portugal) Halldór RUNÓLFSSON (Ísland) Jean- Claude ROUBY (France) Liisa SIHVONEN (Suomi/ Finland) Marc WIRTOR (Luxembourg)
Requests for inspection of European experts lists The list of European experts is available for inspection on request at the EMEA offices.
2 Ersatte Annika WENNBERG fr. o. m. mötet i oktober 2000.
Requests may be made either in writing to the EMEA or sent to the following e-mail addresses:
4 Ersatte Christos HIMONAS fr. o. m. mötet i april 2000.
Human medicines’ experts list Veterinary medicines’ experts list Inspectors experts list
EMEA/ MB/ 050/ 00 Allmän rapport 2000 Bilaga 6 Medlemmar i kommittén för särläkemedel
human_experts@emea. eudra. org vet_experts@emea. eudra. org inspectors_experts@emea. eudra. org
España
Media and press contacts
Josep TORRENT i FARNELL
Representatives of the media should contact the following people for information:
Belgique/ België Danmark Deutschland / Greece αδάλλΕ